Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

39.25 +0.04 (+0.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
From Exelixis, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
From Exelixis, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
From Exelixis, Inc.
Via Business Wire
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
From Exelixis, Inc.
Via Business Wire
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.